• BioVie will present Phase 2 bezisterim Long COVID findings, including previously undisclosed biomarker data, on November 13, 2026, in Nice, France.
• The randomized, placebo-controlled ADDRESS-LC trial showed a consistent trend toward improvement across most patient-reported and objective efficacy measures.
• Prespecified exploratory analyses found the greatest benefits in patients with more severe fatigue, post-exertional malaise or cognitive impairment, including statistically significant improvements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020900PRIMZONEFULLFEED9867953) on November 02, 2026, and is solely responsible for the information contained therein.